CVE:SLS

Solaris Resources (SLS) Stock Forecast, Price & News

C$6.15

-0.17 (-2.69%)

(As of 02/8/2021)

Add

Compare

Today's Range: C$5.95
▼
C$6.35
50-Day Range: N/A
52-Week Range: C$1.38
▼
C$7.09

Volume: 53,313 shs
Average Volume: 132,199 shs
Market Capitalization: C$643.73 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: N/A

30 days | 90 days | 365 days | Advanced Chart

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for Solaris Resources and its competitors with MarketBeat's FREE daily newsletter.

About Solaris Resources

SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapeutics for a broad range of cancer indications. SELLAS' lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, NPS, is a HER2-directed cancer immunotherapy with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following standard of care.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: CVE
Industry: Pharmaceutical Preparation Manufacturing
Sub-Industry: N/A
Sector: Manufacturing
Current Symbol: CVE:SLS
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: www.sellaslifesciences.com
Phone: N/A
Fax: N/A
Employees: 7
Year Founded: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 104,671,000
Free Float: N/A
Market Cap: C$643.73 million
Optionable: Optionable

Company Calendar

Today: 5/28/2022
Next Earnings (Estimated): 8/12/2022

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Solaris Resources.

0.0 Community Rank

Outperform Votes
Solaris Resources has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Solaris Resources has received 1 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Solaris Resources has received 100.00% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Solaris Resources and other stocks. Vote “Outperform” if you believe SLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Solaris Resources does not currently pay a dividend.
Dividend Growth
Solaris Resources does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Solaris Resources insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Solaris Resources (CVE:SLS) Frequently Asked Questions

When is Solaris Resources' next earnings date?: Solaris Resources is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022.
View our earnings forecast for Solaris Resources.
Who are some of Solaris Resources' key competitors?: Some companies that are related to Solaris Resources include Kadmon (KDMN), HydrogenOne Capital Growth (HGEN), TherapeuticsMD (TXMD), 4D pharma (LBPSW), BetaShares Global Healthcare ETF - Currency Hedged (DRUG), BriaCell Therapeutics (BCTXW), eFFECTOR Therapeutics (EFTRW), Esports Entertainment Group (GMBLW), Pantera Minerals (PFE) and Sinovac Biotech (SVA).
View all of SLS's competitors.
What is Solaris Resources' stock symbol?: Solaris Resources trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SLS."
How do I buy shares of Solaris Resources?: Shares of SLS and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.
What is Solaris Resources' stock price today?: One share of SLS stock can currently be purchased for approximately C$6.15.
How much money does Solaris Resources make?: Solaris Resources has a market capitalization of C$643.73 million.
How many employees does Solaris Resources have?: Solaris Resources employs 7 workers across the globe.
What is Solaris Resources' official website?: The official website for Solaris Resources is www.sellaslifesciences.com.

This page was last updated on 5/28/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.